Antrin motexafin lutetium: Phase I

PCYC reported preliminary results from a 75-patient, dose-escalation U.S. Phase I trial showing that

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE